Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
The degree of structural damage present initially may influence durability of response
Your provider walks you through technique during your consultation, and your prescription ships with clear instructions
What distinguishes ipamorelin from every other growth hormone releasing peptide (GHRP) is its selectivity: it releases GH without stimulating cortisol, ACTH, or prolactin, even at doses more than 200 times the amount needed for maximal GH release
Published records include a small healthy-volunteer PK/PD study and a phase 2 postoperative-ileus trial
J Drug Deliv Sci Technol 86:104694
